Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.

Matthew C BakerYashaar ChaichianMark GenoveseVimal K DerebailPanduranga RaoWinn ChathamMichael BubbSam LimHooman HajianOksana GurtovayaUptal PatelJames Tumlin

Published in: RMD open (2021)

NCT03285711.

Keyphrases

phase ii
double blind
placebo controlled
clinical trial
systemic lupus erythematosus
open label
disease activity
phase iii
study protocol
rheumatoid arthritis
randomized controlled trial